Search Results - "Koldenhof, J. J."

Frailty and checkpoint inhibitor toxicity in older patients with melanoma by Bruijnen, Cheryl P., Koldenhof, José J., Verheijden, Rik J., Bos, Frederiek, Emmelot‐Vonk, Mariëlle H., Witteveen, Petronella O., Suijkerbuijk, Karijn P. M.

“…Background Immune checkpoint inhibitors (ICIs) can cause immune‐related adverse events (irAEs) that range from mild to life‐threatening. Age itself does not…”
Get full text

Prospective practice survey of management of cetuximab-related skin reactions by Lugtenberg, R. T., Boers-Doets, C. B., Witteveen, P. O., van Herpen, C. M. L., Wymenga, A. N. M., de Groot, J. W. B., Hoeben, A., del Grande, C., van Doorn, B., Koldenhof, J. J., Driessen, C. M. L., Gelderblom, H.

“…Purpose Evidence-based guidelines on how to prevent or treat cetuximab-related skin reactions are lacking and multiple care and management strategies are used…”
Get full text

Predicting Anxiety in Hospitalized Cancer Patients by van den Brekel, Lieke, van der Baan, Frederieke H., Zweers, Danielle, Koldenhof, José J., Vos, J. Bernard H., de Graeff, Alexander, Witteveen, Petronella O., Teunissen, Saskia C.C.M.

“…Anxiety in patients with cancer is highly prevalent; yet it remains underestimated and inadequately assessed. Little is known about predictors for anxiety in…”
Get full text

What patients with advanced cancer experience as helpful in navigating their life with a long-term response: a qualitative study by Zwanenburg, Laura C., van der Lee, Marije L., Koldenhof, José J., Suijkerbuijk, Karijn P. M., Schellekens, Melanie P. J.

“…Purpose Despite improved survival for people with advanced cancer due to new medical treatments, a growing group of long-term responders (LTRs) has to learn to…”
Get full text

Living in the twilight zone: a qualitative study on the experiences of patients with advanced cancer obtaining long-term response to immunotherapy or targeted therapy by Zwanenburg, Laura C., Suijkerbuijk, Karijn P. M., van Dongen, Sophie I., Koldenhof, José J., van Roozendaal, Anne S., van der Lee, Marije L., Schellekens, Melanie P. J.

“…Purpose The introduction of immunotherapy and targeted therapy has drastically improved the life expectancy of patients with advanced cancer. Despite improved…”
Get full text

Predictive value of each geriatric assessment domain for older patients with cancer: A systematic review by Bruijnen, Cheryl P., van Harten-Krouwel, Diny G., Koldenhof, José J., Emmelot-Vonk, Mariëlle H., Witteveen, Petronella O.

“…A geriatric assessment (GA) is increasingly used to help guide treatment decisions in older patients with cancer. However, there is no consensus regarding…”
Get full text

Cerebrospinal fluid lymphocytosis: a hallmark of neurological complications during checkpoint inhibition by Tonk, Erwin H.J., Snijders, Tom J., Koldenhof, José J., van Lindert, Anne S.R., Suijkerbuijk, Karijn P.M.

Get full text

Patient-reported outcome measures in a pharmacokinetic study with sunitinib, a prospective cohort study by Koldenhof, J. J., Lankheet, N. A. G., Steeghs, N., Teunissen, S. C. C. M., Witteveen, P. O.

“…Purpose During treatment with tyrosine kinase inhibitors, such as sunitinib, patients experience treatment and/or disease-related symptoms. Although…”
Get full text

HUMAN URETHRA-ON-A-CHIP TO STUDY URETHRAL STICTURE DISEASE by de Graaf, P, Xing, Z, Koldenhof, J, Wyndaele, M, de Kort, L

Get full text

1741 Patient reported symptoms and stepwise symptom management in patients on epidermal growth factor inhibitors by Koldenhof, J, Langenberg, M, Teunissen, S

Get full text

BRAF/MEK-inhibition for patients with metastatic melanoma: Towards patient-centered care by Koldenhof, J J, Vervoort, S C, Nierop, C A, Suijkerbuijk, K P

Get full text

Cerebrospinal fluid lymphocytosis: A hallmark of neurological immune related adverse events (irAEs) during checkpoint inhibitor treatment by Suijkerbuijk, K.P., De Vos, F.Y.F.L., Koldenhof, J.J., Snijders, T.J.

Get full text

Validation of 11 added items of the outpatient version of the Utrecht Symptom Diary in patients receiving chemotherapy or targeted therapy by Koldenhof, Josephine J., Akpobome, Bernice O., Zweers, Danielle, Klaasse, Stance, Teunissen, Saskia C. C. M., Witteveen, Petronella O., Suijkerbuijk, Karijn P. M., de Graeff, Alexander, van der Baan, Frederieke H.

“…Introduction The Utrecht Symptom Diary (USD) is a validated Dutch patient-reported outcome measurement (PROM) tool - based on the Edmonton Symptom Assessment…”
Get full text

Validation of the Dutch version of the Edmonton Symptom Assessment System by Baan, Frederieke H., Koldenhof, Josephine J., Nijs, Ellen J., Echteld, Michael A., Zweers, Danielle, Hesselmann, Ginette M., Vervoort, Sigrid C., Vos, Jan B., Graaf, Everlien, Witteveen, Petronella O., Suijkerbuijk, Karijn P., Graeff, Alexander, Teunissen, Saskia C.

“…ABSTRACT Background The Utrecht Symptom Diary (USD) is a Dutch and adapted version of the Edmonton Symptom Assessment System, a patient‐reported outcome…”
Get full text

Patient‐reported symptoms and stepwise symptom management in patients on epidermal growth factor inhibitors: A retrospective, descriptive cohort study by Koldenhof, J.J., Langenberg, M.H.G., Witteveen, P.O., Teunissen, S.C.C.M.

“…Adverse events (AEs) of epidermal growth factor inhibitors (EGFRi) influence well‐being with a risk to dose modifications (DMs). Hereby, clinical benefit of…”
Get full text

Symptoms from treatment with sunitinib or sorafenib: a multicenter explorative cohort study to explore the influence of patient-reported outcomes on therapy decisions by Koldenhof, J. J., Witteveen, P. O., de Vos, R., Walraven, M., Tillier, C. N., Verheul, H. M. W., Teunissen, S. C. C. M.

“…Purpose Optimal long-lasting treatment with sunitinib and sorafenib is limited by dose modifications (DMs) due to adverse events (AEs). These AEs may be…”
Get full text

Diarrhoea during checkpoint blockade, not always colitis by Koldenhof, Josephine J., Suijkerbuijk, Karijn P.M.

Get full text

Patient-Reported Outcomes During Checkpoint Inhibition: Insight into Symptom Burden in Daily Clinical Practice by Koldenhof, Josephine J., van der Baan, Frederieke H., Verberne, Elisabeth G., Kamphuis, Annemarleen M., Verheijden, Rik J., Tonk, Erwin H., van Lindert, Anne S., van der Stap, Janneke, Teunissen, Saskia C., Witteveen, Petronella O., Suijkerbuijk, Karjin P.

“…While praised for inducing durable anti-tumour responses, immune checkpoint inhibitors (ICI) also cause immune-related adverse events (irAEs) that can vary in…”
Get full text

8105 POSTER How to reach targets with a SIG by van Riel, C, Koldenhof, J, Mallo, H, Huisman, C

Get full text

1197PCerebrospinal fluid lymphocytosis: A hallmark of neurological immune related adverse events (irAEs) during checkpoint inhibitor treatment by Suijkerbuijk, K P, De Vos, F Y F L, Koldenhof, J J, Snijders, T J

Get full text